ENDURE: Engagement with Novel Therapies and Decision Making ThroUgh BReast Cancer Education

Investigations and Clinical Applications of CDK4/6 Inhibitors in Breast Cancer

This activity has been jointly planned and implemented by the Duke University Health System Department of Clinical Education and Professional Development and Catamount Medical Education for the advancement of patient care. The Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the health care team.

This CE activity is supported by an educational grant from Pfizer Inc.

Scroll to the Bottom of this Information to Begin this Course

Release date: December 30, 2016

Valid through: December 30, 2017

Specialty: Oncology

Topic: Breast Cancer

Media: Internet

Estimated time to complete activity: 45 minutes

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice nurses, physician assistants, nurses, pharmacists and other health care professionals involved in the management of patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current research on the use of CDK4/6 inhibitors for breast cancer patients, including pre-clinical data, biomarker targets and sensitivity and resistance mechanisms
  • Discuss the MOA of CDK4/6 inhibitors
  • Review clinical trial data on CDK4/6 inhibitors, including efficacy and safety data
  • Identify appropriate patient selection for the use of CDK4/6 inhibitors
  • Review the toxicity profiles of CDK4/6 inhibitors
  • Apply strategies to manage neutropenia and other adverse events
  • Discuss existing and emerging clinical trial data associated with adverse events of combination therapies using CDK4/6 inhibitors
  • Discuss ways to enhance clinician/patient communication to improve patient outcomes
  • Apply shared decision-making strategies in the management of patients with breast cancer

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credits
  • Pharmacists 0.75 contact hours (0.075 CEUs)
  • Nurses0.75 contact hours

All other health care professionals completing this course will be issued a statement of participation.

Faculty

Linda M. Sutton, MD

Medical Director, Duke Cancer Network
Associate Professor of Medicine
Duke University Medical Center
Durham, North Carolina

Richard S. Finn, MD

Associate Professor of Medicine
The Geffen School of Medicine at UCLA
Department of Medicine
Division of Hematology/Oncology
Los Angeles, California

P. Kelly Marcom, MD

Associate Professor of Medicine
Director, DCI Breast Cancer Program
DCI Associate Director of Breast Cancer Clinical Research
Duke University Medical Center
Durham, North Carolina

Physician Continuing Medical Education

Credit Designation

Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 0.75 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement

This activity has been planned and implemented by the Duke University Health System Department of Clinical Education and Professional Development, The Duke Cancer Network and Catamount Medical Education for the advancement of patient care. The Duke University Health System Department of Clinical Education & Professional Development is accredited by the Accreditation Council for Pharmacy Education (ACPE) to provide continuing education for the health care team.

Credit Designation

Duke University Health System Department of Clinical Education and Professional Development designates this knowledge-based activity for a maximum of 0.75 ACPE credit hours.
Universal Activity Number: 0851-9999-16-250-H01-P

Type of Activity

Knowledge

Nursing Continuing Education

Credit Designation

Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 0.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in this activity.

Disclosures of Conflicts of Interest

Duke University Health System Clinical Education and Professional Development has implemented a process to resolve any potential conflicts of interest for each continuing education activity in order to help ensure content objectivity, independence, fair balance, and the content that is aligned with the interest of the public.

It is the policy of the Duke University Health System Clinical Education and Professional Development to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity.

The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CE activity: Kerri Dalton, MSN, RN, AOCNS; Susan Denner, MD, MS; Donna Topping, PharmD; Melanie Watson, MSN, RN.

The following speakers and/or planning committee members have indicated that they have relationship(s) with industry to disclose:

Richard S. Finn, MD
  • Consultant and Principal Investigator: Pfizer and Bayer
  • Consultant and Advisory Board Member: Novartis and Bristol-Myers Squibb
P. Kelly Marcom, MD
  • Principal Investigator: Abbott Pharmaceuticals, Genentech, Johnson & Johnson, and Novartis
Linda M. Sutton, MD
  • Member of Data Safety Monitoring Committee: GW Pharma

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the period December 30, 2016 through December 30, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form.

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded.

If you successfully complete the post-test (score of 70% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you receive a score of 74% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Presentation Slides

Please click here for Part 1 of the presentation, and click here for Part 2.